FinnGen provides genetic insights from a well-phenotyped isolated population
Approved
Classifications
MinEdu publication type
A1 Journal article (peer-reviewed)
Definition
Article
Target group
Scientific
Peer reviewed
Peer-reviewed
Article type
Journal article
Host publication type
Journal
Publication channel information
Title of journal/series
Nature
ISSN (print)
0028-0836
ISSN (electronic)
1476-4687
ISSN (linking)
0028-0836
Publisher
Nature publishing group
Publication forum ID
63759
Publication forum level
3
Country of publication
United Kingdom
Internationality
Yes
Detailed publication information
Publication year
2023
Reporting year
2023
Journal/series volume number
613
Journal/series issue number
7944
Page numbers
508-518
DOI
10.1038/s41586-022-05473-8
Language of publication
English
Co-publication information
International co-publication
Yes
Co-publication with a company
Yes
Availability
Link to online publication
Classification and additional information
MinEdu field of science classification
3111 Biomedicine
Funding information
Funding information in the publication
The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie, AstraZeneca UK, Biogen, Bristol Myers Squibb (and Celgene Corporation & Celgene International II), Genentech, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Pfizer, GlaxoSmithKline Intellectual Property Development, Sanofi US Services, Maze Therapeutics, Janssen Biotech, Novartis, and Boehringer Ingelheim.
Source database ID
WoS ID
WOS:000928299100001
Scopus ID
2-s2.0-85146485867
Other database ID
PMID: 36653562